Biopharma Week in Review - October 21, 2024

266 Views22 Oct 2024 23:20
Issuer-paid
Last week, LBPH was acquired, providing a boost to comps PRAX, MRNS, JAZZ, and DRUG. Biopharma M&A may start seeing an uptick after a slow summer.
What is covered in the Full Insight:
  • Biopharma M&A Activities
  • RNA Editing and Regulatory Pathways
  • Clinical Updates: EXEL, JSPR, JAZZ, MGTX, AURA
  • Regulatory and Trial Setbacks: NVAX, GILD
  • Market Performance and Outlook
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 8-minute read)
Related Insights
More »
    Loading
Trending Collections
More »
    Loading
Trending Insights
More »
    Loading
Top Unpaywalled Insights
More »
    Loading
Discussions
(Paid Plans Only)
chart-bar
  • Biopharma Week in Review - October 21, 2024
    22 Oct 2024
x